[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:blastic-plasmacytoid-dendritic-cell-neoplasm:interleukin-3-receptor-subunit-alpha":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Blastic Plasmacytoid Dendritic Cell Neoplasm","Interleukin-3 Receptor Subunit Alpha",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03113643","SL-401 in Combination With Azacitidine or Azacitidine\u002FVenetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",[12],"Phase 1","RECRUITING","2026-08-26T02:16:52.995882Z","2026-05-05T02:35:31.898696Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04318678","CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",[12],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.730542Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05476770","Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies",[12],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:27.744798Z"]